Delstrigo (Doravirine/Lamivudine/Tenofovir disoproxil fumarate) for HIV

Overview
Delstrigo is a prescription drug approved by the Food and Drug Administration (FDA) as a complete regimen to treat HIV-1 infection in adults. Delstrigo is a combination drug composed of Doravirine, Lamivudine, and Tenofovir disoproxil fumarate, which are also known respectively by the abbreviations DOR, 3TC, and TDF. Doravirine is an antiretroviral drug of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Lamivudine and Tenofovir disoproxil fumarate are both antiretroviral medications of the nucleoside reverse transcriptase inhibitor (NRTI) class. All three drugs are believed to work by preventing HIV from replicating in cells.

How do I take it?
Prescribing information states that Delstrigo is taken once daily. Delstrigo comes in tablet form.

Side effects
The FDA-approved label for Delstrigo lists common side effects including dizziness, nausea, and unusual dreams. Rare but serious side effects listed for Delstrigo include kidney problems, bone loss, and immune reconstitution syndrome (an inflammatory disorder).

For more details about this treatment, visit:

Delstrigo – Merck